Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors (Q36883658)
scientific article published on February 2007
Language:
(P31) (Q13442814)
(Q7318358)
(P304) 15-27
(P433) 1
(P478) 8
(P577) Thursday, February 1, 2007
(P921) (Q413299)
(Q539568)
(P1433) (Q3510796)
(P1476) "Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors" (language: en)
(P2093) Elwyn Cabebe
Heather Wakelee
(P2860) (Q40620827)
(Q33369361)
(Q29617585)
(Q39714055)
(Q34563207)
(Q80120173)
(Q40657525)
(Q46972019)
(Q45713422)
(Q27860595)
(Q34323659)
(Q46499714)
(Q70493357)
(Q46652649)
(Q29615133)
(Q37132598)
(Q40930925)
(Q44150789)
(Q78598197)
(Q40623012)
(Q31006650)
(Q36618743)
(Q27860704)
(Q47834118)
(Q35296110)
(Q40801255)
(Q41372600)
(Q28200155)
(Q28262507)
(Q28241070)
(Q45025054)
(Q64449297)
(Q29547546)
(Q40401032)
(Q46068556)
(Q29615390)
(Q72410073)
(Q28251373)
(Q42809733)
(Q28278736)
(Q34157098)
other details
description scientific article published on February 2007

External Links